HIGHLIGHTS
- who: Mohamed S. Abdelbaki from the Institutional review board (IRB) approval was obtained at NationwideThe Division of Hematology and Oncology, StLouis Children`s Hospital, Washington University, School of Medicine in StLouis, Washington University, St. Louis, Missouri, USA have published the article: An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors, in the Journal: (JOURNAL) of April/15,/2019
SUMMARY
Premedication with an antihistamine was considered optional for the first 2 patients; however, premedication was required for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.